Suchergebnisse - "DIFFUSE large B-cell lymphomas"

Evaluating the Role and Policy Implications of Using External Evidence in Survival Extrapolations: A Case Study of Axicabtagene Ciloleucel Therapy for Second-Line DLBCL.

Autoren: Harper, Sam Afonso, Daniela Watts, Karina et al.

Quelle: PharmacoEconomics. Nov2025, Vol. 43 Issue 11, p1293-1307. 15p.

Schlagwörter: TECHNOLOGY assessment, DIFFUSE large B-cell lymphomas, CHIMERIC antigen receptors, CLINICAL decision making, MEDICAL technology, SURVIVAL analysis (Biometry)

Histopathological patterns and immunophenotyping of feline lymphomas and incidence in Metropolitan Bangkok, Thailand.

Autoren: Jedsada Siripoonsub Sirintra Sirivisoot Somporn Techangamsuwan et al.

Quelle: Veterinary World. Oct2024, Vol. 17 Issue 10, p2225-2234. 10p.

Schlagworte: Diffuse large B-cell lymphomas, T-cell lymphoma, B cells, Veterinary medicine, CD20 antigen, Immunochemistry, Cat diseases

Rethinking the role of surgical resection in the management of primary pituitary lymphoma.

Autoren: Filo, Jean Zhao, Maryann Orrego-Gonzalez, Eduardo et al.

Quelle: British Journal of Neurosurgery. Dec2025, Vol. 39 Issue 6, p844-848. 5p.

Schlagwörter: *DIFFUSE large B-cell lymphomas, *DIAGNOSIS, *CHEMORADIOTHERAPY, *SURGICAL excision, *THERAPEUTICS

Dose and Duration of Upfront Steroid Administration Have no Prognostic Impact in Dogs With Multicentric Diffuse Large B‐Cell Lymphoma.

Autoren: Maga, Ilaria Sabattini, Silvia Martini, Valeria et al.

Quelle: Veterinary & Comparative Oncology. Dec2025, Vol. 23 Issue 4, p509-517. 9p.

Schlagwörter: *STEROIDS, *DIFFUSE large B-cell lymphomas, *DIAGNOSIS, *CANCER chemotherapy, *DRUG resistance in cancer cells, *TREATMENT effectiveness, *DOGS, *IMMUNOTHERAPY

Study on the regulation of Treg cell infiltration by EZH2 through CXCR4/CXCL12 in diffuse large B-cell lymphoma.

Autoren: Wang, Hongxia Liang, Dongyu Qian, Yu et al.

Quelle: Clinical & Experimental Medicine. 11/25/2025, Vol. 26 Issue 1, p1-16. 16p.

Schlagwörter: *CXCR4 receptors, *DIFFUSE large B-cell lymphomas, *IMMUNOLOGICAL tolerance, *TUMOR microenvironment, *METHYLTRANSFERASES, *REGULATORY T cells, *IMMUNOTHERAPY, *STROMAL cell-derived factor 1

Tumor metabolic heterogeneity based on ¹⁸F-FDG PET/CT is a predictor of outcome in diffuse large B-cell lymphoma.

Autoren: Xin, Wenchong Wang, Fei Lu, Luo et al.

Quelle: BMC Cancer. 11/24/2025, Vol. 25 Issue 1, p1-13. 13p.

Schlagwörter: *DIFFUSE large B-cell lymphomas, *PROGNOSIS, *POSITRON emission tomography computed tomography, *SURVIVAL analysis (Biometry), *INDIVIDUALIZED medicine, *DRUG resistance

Sodium-myoinositol cotransporter-1 downstream of m6A methyltransferase WTAP exerts a potential carcinogenicity in diffuse large B-cell lymphoma progression.

Autoren: Li, Xinyang He, Xiaowei Sun, Ying et al.

Quelle: Journal of Translational Medicine. 11/18/2025, Vol. 23 Issue 1, p1-15. 15p.

Schlagwörter: *DIFFUSE large B-cell lymphomas, *ONCOGENES, *METHYLTRANSFERASES, *APOPTOSIS, *CELL proliferation, *RNA methylation, *NEOPLASTIC cell transformation

Added prognostic value of baseline pre-infusion ¹⁸F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy.

Autoren: Mirshahvalad, Seyed Ali Kohan, Andres Kulanthaivelu, Roshini et al.

Quelle: Scientific Reports. 11/11/2025, Vol. 15 Issue 1, p1-11. 11p.

Schlagwörter: *DIFFUSE large B-cell lymphomas, *POSITRON emission tomography computed tomography, *CHIMERIC antigen receptors, *PROGNOSIS, *PATHOLOGY, *SURVIVAL analysis (Biometry), *INFUSION therapy

Bispecific antibody combination therapies in diffuse large B‐cell lymphoma.

Autoren: Harrop, Sean Minson, Adrian Steiner, Thiago M. et al.

Quelle: British Journal of Haematology. Nov2025, p1. 12p. 1 Illustration.

Schlagwörter: *BISPECIFIC antibodies, *DIFFUSE large B-cell lymphomas, *DRUG resistance, *THERAPEUTICS, *THERAPEUTIC complications, *ANTINEOPLASTIC agents, *CLINICAL trials

Transformation of Primary Small Intestinal Follicular Lymphoma to CD20-Negative Diffuse Large B-Cell Lymphoma following Rituximab Treatment: A Case Report.

Autoren: Kitamura, Masafumi Sakamoto, Hirotsugu Shinozaki, Satoshi et al.

Quelle: Case Reports in Gastroenterology. Nov2025, Vol. 19 Issue 1, p718-725. 8p. 5 Illustrations.

Schlagwörter: *FOLLICULAR lymphoma, *DIFFUSE large B-cell lymphomas, *CELL transformation, *GASTROINTESTINAL system, *CD20 antigen, *RITUXIMAB, *ENDOSCOPIC surgery, *OPERATIVE surgery

Efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted CAR-T therapy: systematic review and meta-analysis.

Autoren: Yu, Yanying Xiang, Zhiyong Hou, Xiaorong et al.

Quelle: Leukemia & Lymphoma. Nov2025, p1-12. 12p. 6 Illustrations.

Schlagwörter: *RADIOTHERAPY, *DIFFUSE large B-cell lymphomas, *CYTOKINE release syndrome, *CHIMERIC antigen receptors, *PROGRESSION-free survival, *TREATMENT effectiveness

Ferroptosis-related gene analysis revealing novel biomarkers and therapeutic targets in diffuse large B-cell lymphoma.

Autoren: Liu, Lushe Guo, Liqun Zhang, Huiyang et al.

Quelle: Scientific Reports. 11/4/2025, Vol. 15 Issue 1, p1-18. 18p.

Schlagwörter: *DIFFUSE large B-cell lymphomas, *BIOMARKERS, *GENOMICS, *PROGNOSTIC models, *IMMUNE response, *CELL death, *DRUG target, *CANCER research

Prognostic Value of Nutritional Index in Patients with Diffuse large B Cell Lymphoma.

Autoren: El-Shamy, Mohamed Gamal Abd El-Halim, Ayman Fathy Hassan, Kholoud Mohamed et al.

Quelle: Zagazig University Medical Journal. Nov2025, Vol. 31 Issue 11, p5408-5419. 12p.

Schlagwörter: *DIFFUSE large B-cell lymphomas, *PROGNOSIS, *TREATMENT effectiveness, *NON-Hodgkin's lymphoma, *THERAPEUTICS, *NUTRITIONAL assessment, *BIOMARKERS

Diffuse Large B‐Cell Lymphoma Combined With Paroxysmal Nocturnal Hemoglobinuria: A Rare Case Report.

Autoren: Liu, Zhen zhen Di, Da lin Feng, An hua et al.

Quelle: Clinical Case Reports. Nov2025, Vol. 13 Issue 11, p1-7. 7p.

Schlagwörter: *DIFFUSE large B-cell lymphomas, *PAROXYSMAL hemoglobinuria, *CLINICAL medicine, *AUTOIMMUNE hemolytic anemia, *HEMATOLOGIC malignancies, *ACUTE myeloid leukemia, *MYELODYSPLASTIC syndromes, *DRUG therapy

Diffuse Large B‐Cell Lymphoma of the Thyroid in a Patient With Hashimoto Thyroiditis: A Diagnostic Dilemma.

Autoren: Karki, Shravya Singh Pandey, Shivam Karki, Smriti et al.

Quelle: Clinical Case Reports. Nov2025, Vol. 13 Issue 11, p1-5. 5p.

Schlagwörter: *DIFFUSE large B-cell lymphomas, *THYROID gland, *CANCER chemotherapy, *DIAGNOSIS, *THYROID cancer, *CORE needle biopsy, *NEEDLE biopsy, *AUTOIMMUNE thyroiditis

Safety profiles in elderly patients with DLBCL on first-line Pola-R-CHP: a claims database study in Japan.

Autoren: Saito, Yo Oda, Tetsuro Nakanishi, Shimpei et al.

Quelle: Leukemia & Lymphoma. Nov2025, p1-13. 13p. 4 Illustrations.

Schlagwörter: *DIFFUSE large B-cell lymphomas, *SAFETY, *MEDICAL databases, *DOXORUBICIN, *COMBINATION drug therapy, *OLDER people, *FEBRILE neutropenia

Geografische Kategorien: JAPAN

Spinal manifestations of diffuse large B-cell lymphoma.

Autoren: Amelot, Aymeric Terrier, Louis-Marie Cognacq, Gabrielle et al.

Quelle: Spine Journal. Nov2025, Vol. 25 Issue 11, p2536-2544. 9p.

Schlagwörter: *DIFFUSE large B-cell lymphomas, *NON-Hodgkin's lymphoma, *METASTASIS, *PROPORTIONAL hazards models, *SURVIVAL analysis (Biometry), *PROGNOSIS, *DEMOGRAPHIC characteristics, *SPINAL cord cancer

Machine learning-based risk prediction model for central nervous system involvement in diffuse large B-cell lymphoma.

Autoren: Ismayilov, Rashad Ozdede, Murat Uner, Aysegul et al.

Quelle: Leukemia & Lymphoma. Nov2025, Vol. 66 Issue 11, p2054-2063. 10p.

Schlagwörter: *CENTRAL nervous system, *DIFFUSE large B-cell lymphomas, *PROGNOSTIC models, *MACHINE learning, *CANCER treatment, *PREDICTIVE validity, *RISK assessment

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events.

Autoren: Derenzini, Enrico Gibb, Adam Kwiatek, Michał et al.

Quelle: Leukemia & Lymphoma. Nov2025, Vol. 66 Issue 11, p1990-2002. 13p.

Schlagwörter: *DIFFUSE large B-cell lymphomas, *ANTIBODY-drug conjugates, *ADVERSE health care events, *ANTINEOPLASTIC agents, *MEDICATION safety, *PHARMACOLOGY

MTV‐guided radiotherapy bridging in large B‐cell lymphoma patients receiving CD19 CAR T‐cell therapy.

Autoren: Kuhnl, Andrea Bouziana, S. Barrington, S. F. et al.

Quelle: British Journal of Haematology. Nov2025, Vol. 207 Issue 5, p2173-2177. 5p.

Schlagwörter: *RADIOTHERAPY, *DIFFUSE large B-cell lymphomas, *CLINICAL trials, *THERAPEUTICS, *CHIMERIC antigen receptors, *RESEARCH protocols